MESO

Mesoblast (MESO)

About Mesoblast (MESO)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Details

Daily high

$18.42

Daily low

$17.96

Price at open

$18.09

52 Week High

$22.00

52 Week Low

$9.61

Market cap

2.3B

Dividend yield

0.00%

Volume

164,308

Avg. volume

227,145

P/E ratio

-20.94

Mesoblast News